President Donald Trump announced a phased tariff plan on imported generic drugs, granting a two-year zero-tariff window before a 100% levy takes effect in August 2028 and rises to 200% in 2029. Industry executives warn the policy will drive up medication costs for U.S. consumers.
Imported generic medications will face zero tariffs for two years beginning August 1, according to an announcement by President Donald Trump on Truth Social. The administration’s stated goal is to force pharmaceutical companies to reshore generic pharmaceutical production back into the United States, where generic prescriptions account for more than 90% of all filled medications.
Industry Executives Warn of Price Surges and Margin Pressures
Major generic drug manufacturers have responded with alarm to the tariff schedule, noting that the sector operates on slender financial cushions that cannot absorb multi-hundred-percent duties. Erez Israeli, chief executive of Indian drugmaker Dr. Reddy’s Laboratories, told CNBC’s ‘Inside India’ that generic medications represent a low-margin business.
Israeli added that the tariff burden will inevitably pass straight to patients, driving up medication prices in the magnitude of the tariff. Echoing those concerns, Namit Joshi, chair of the Pharmaceuticals Export Promotion Council of India, noted that right now, we are operating on a very thin margin.
The U.S. market represents a vital destination for international pharmaceutical exporters. India supplies roughly half of all generic prescriptions filled in the United States, according to data from the Senate Committee on Aging cited by Time Magazine.
Health Policy Experts Question Feasibility of Rapid Onshoring
Health policy specialists remain skeptical that financial penalties alone will persuade manufacturers to relocate complex manufacturing facilities to U.S. soil within the allotted two-year window. Marta Wosińska, a senior fellow at the Brookings Institution’s Center on Health Policy, told CBS News that duties cannot achieve onshoring in isolation.
Building compliant pharmaceutical plants requires highly specialized infrastructure and strict quality controls. Experts interviewed by CBS News emphasized that these are facilities that require very specific equipment and infrastructure and quality standards. Dr. Reddy’s CEO Erez Israeli further noted that moving operations would realistically take four to seven years, rendering a two-year timeline impractical given higher operating expenses inside the U.S.
White House spokesman Kush Desai defended the timeline to CBS News, pointing to administration support mechanisms such as full equipment expensing and citing prior negotiations. The President’s resounding success securing firm reshoring plans from global drugmakers as part of our most-favored-nations deals and Section 232 tariff program for branded drugs is proof that this administration has a track record of success to get critical manufacturing back into the United States, Desai said in an email.
Stock Markets React as Patient Advocates Sound the Alarm
Financial markets reacted swiftly to the tariff announcement. Shares of major international generic manufacturers fell following the news, with Swiss drugmaker Sandoz dropping as much as 4.2% in Zurich, as reported by the Los Angeles Times.
Patient advocacy groups warned that the financial pressure could jeopardize access to essential daily medications. Merith Basey, CEO of Patients For Affordable Drugs, cautioned Reuters that imposing massive tariffs on generic medicines risk making lower-cost generic drugs millions of Americans rely on more expensive and harder to access.
Analysts at Nomura noted in a research report highlighted by CNBC that while Indian firms are unlikely to relocate manufacturing due to low economic viability, the proposed duties could prompt manufacturers to raise prices to protect profits.
Keep reading